► Multiple sclerosis (MS), of which relapsing forms (RMS) are the most common [1] [2] [3] , imposes a considerable economic burden on healthcare systems 4 . ► Glatiramer acetate (GA; COPAXONE ® ) 20 mg/ml once-daily has demonstrated long-term (over 20 years), real-world efficacy and safety for the treatment of RMS and has low monitoring, testing and administration requirements 5, 6 . ► Teva has developed GA 40 mg/ml three times a week to offer patients the same known efficacy and safety benefits of GA 20 mg/ml once-daily but with a less intense treatment regimen.
Switching from GA 20 mg/ml once-daily to other DMTs* at an annual rate of 8%
Medicine costs
Administration, testing and monitoring costs *Alemtuzumab 10 mg/ml, dimethyl fumarate 240 mg, fingolimod 0.5 mg, natalizumab 300 mg and teriflunomide 14 mg. 
METHODS

Model specifications
Population
The eligible population was the estimated number of individuals with MS in Spain, based on:
► The total Spanish population reported as of mid-2014 -46,820,084 10 .
► The prevalence of MS per 100,000 Spanish individuals -90 -which was derived from a cross-sectional study reporting the prevalence of MS over a 17-year period in Osona, Catalonia, Spain
11
. It was assumed this value is representative of the total Spanish population.
Medicine costs
► Medicine costs (cost per pack) for all DMTs, except GA, were sourced from the Spanish General Council of Pharmacists database 12 .
► The cost per pack of GA-based medicines was based on confidential prices agreed with the Spanish Ministry of Health.
► Dosing information (number of packs used per year) were taken from the Summary of Product Characteristics (SmPC) documentation for each medicine 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
► As alemtuzumab is only administered during the first two years of treatment, the number of packs (vials) used per year was calculated according to the recommended adult daily dose, as reported in the SmPC 21 , taking account of the five-year model time horizon.
Administration and additional care costs Administration costs (Table 2) were derived as follows:
► The cost of administering GA-based regimens was based on the assumption that three hours of nurse time would be required to teach people with MS how to self-administer injections, with the cost per nurse hour reported by an analysis of clinical decision making strategies in Spain
23
; it is assumed that administration costs would only be incurred in the first year of treatment.
► It was conservatively assumed that oral treatments would not incur any administration costs.
► Administration costs for alemtuzumab were based on yearly infusion requirements, costed according to the catalogue of diagnostic and therapeutic procedures for Spain 24 , and additional medicine requirements (e.g. methylprednisolone and aciclovir 200 mg) as specified in the SmPC .
► The cost of administering natalizumab was based on yearly infusion requirements, as reported by the catalogue of diagnostic and therapeutic procedures for Spain 24 .
Initiation and monitoring costs (Table 2) were derived as follows:
► Pre-treatment costs included tests recommended by individual SmPC with the assumption that all patients would require an initial neurology outpatient appointment to conduct a baseline magnetic resonance image (MRI) scan 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
► Initiation and monitoring costs while on treatment were based on the frequency of testing required as reported in the SmPC 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , with the cost of testing charged as an outpatient tariff 26 ; for GA 20 mg/ml once-daily and 40 mg/ml three times a week, no monitoring requirements are reported in the SmPCs.
RESULTS
► An estimated 5,084 people with MS received GA 20 mg/ml once-daily in Spain in 2014, corresponding to 12.1% of those receiving DMTs.
► Assuming progressive switching from GA 20 mg/ml once-daily to newly-introduced first-line, and second-line, DMTs at an annual rate of 8%, and accounting for no change in the distribution of the interferons and a population increase of 0.6% per year (Table 3) , total additional expenditure on MS treatments was estimated at €2.60 billion over five years (scenario 1; Figure 2 ).
► Assuming progressive switching from GA 40 mg/ml three times a week to newly-introduced first-line, and second-line, DMTs at a reduced annual rate of 5% due to the benefit of lower rates of IRAEs with improved treatment convenience ( Table 3 ; a 38% reduction compared with GA 20 mg/ml once-daily), total additional expenditure on MS treatments was estimated at €2.57 billion over five years (scenario 2; Figure 2 ).
► In both scenarios, the majority (>95%) of the additional cost arose from the higher acquisition costs of the newly-introduced first-line DMTs (Figure 2 ).
► Overall, compared with GA 20 mg/ml once-daily, GA 40 mg/ml three times a week has the potential to reduce costs of switching by between €5.9 million and €7.2 million annually (Figure 3) , with savings totalling €32.8 million over five years. Table 3 . Current vs revised patient distributions for GA-based treatments based on annual switching rates of 8% (scenario 1; GA 20 mg/ml once-daily) and 5% (scenario 2; GA 40 mg/ml three times a week) 
CONCLUSIONS
►
The tolerability and treatment convenience benefits of GA 40 mg/ml three times a week, compared with GA 20 mg/ml once-daily, may improve patient retention on GA-based treatment regimens and reduce switching to the newly-introduced first-line, and second-line, DMTs; this may generate considerable cost savings for healthcare systems.
